These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 9630823

  • 1. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA, Wood AJ.
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK.
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [Abstract] [Full Text] [Related]

  • 4. Effects of CYP3A inhibition on the metabolism of cilostazol.
    Suri A, Forbes WP, Bramer SL.
    Clin Pharmacokinet; 1999 Jan; 37 Suppl 2():61-8. PubMed ID: 10702888
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dietary salt increases first-pass elimination of oral quinidine.
    Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM.
    Clin Pharmacol Ther; 1997 Mar; 61(3):292-300. PubMed ID: 9084454
    [Abstract] [Full Text] [Related]

  • 7. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED, Walker A, Hoffer C, Sheffels P.
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [Abstract] [Full Text] [Related]

  • 8. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
    Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL.
    Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
    [Abstract] [Full Text] [Related]

  • 9. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
    Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K.
    Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
    [Abstract] [Full Text] [Related]

  • 10. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [Abstract] [Full Text] [Related]

  • 11. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED, Hoffer C, Whittington D, Sheffels P.
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [Abstract] [Full Text] [Related]

  • 12. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ.
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H, Echizen H, Nachi S, Ohnishi A.
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [Abstract] [Full Text] [Related]

  • 15. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, Zanovello P.
    Cancer Res; 2000 Jun 15; 60(12):3232-8. PubMed ID: 10866316
    [Abstract] [Full Text] [Related]

  • 16. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.
    Korhonen T, Tolonen A, Uusitalo J, Lundgren S, Jalonen J, Laine K.
    Br J Clin Pharmacol; 2005 Jul 15; 60(1):69-75. PubMed ID: 15963096
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
    Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI.
    Clin Pharmacol Ther; 1998 Sep 15; 64(3):278-85. PubMed ID: 9757151
    [Abstract] [Full Text] [Related]

  • 18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.
    J Pharmacol Exp Ther; 1999 Sep 15; 290(3):1116-25. PubMed ID: 10454485
    [Abstract] [Full Text] [Related]

  • 19. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
    Zweers-Zeilmaker WM, Van Miert AS, Horbach GJ, Witkamp RF.
    Res Vet Sci; 1999 Feb 15; 66(1):51-5. PubMed ID: 10088712
    [Abstract] [Full Text] [Related]

  • 20. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD.
    Clin Pharmacol Ther; 1998 Aug 15; 64(2):133-43. PubMed ID: 9728893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.